Adult Safety Profile

Demonstrated long-term safety
profile in adults

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent with the Week 16 adult safety profile1

Demonstrated safety profile across 52 weeks in adults

Adverse reactions occurring in ≥1% of adult patients through Week 161
Injection site reaction
DUPIXENTc
(n=529) n (%)		 10%
PLACEBO
(n=517) n (%)		 5%
Conjunctivitisd
DUPIXENTc
(n=529) n (%)		 10%
PLACEBO
(n=517) n (%)		 2%
Blepharitis
DUPIXENTc
(n=529) n (%)		 <1%
PLACEBO
(n=517) n (%)		 <1%
Oral herpes
DUPIXENTc
(n=529) n (%)		 4%
PLACEBO
(n=517) n (%)		 2%
Keratitise
DUPIXENTc
(n=529) n (%)		 <1%
PLACEBO
(n=517) n (%)		 0%
Eye pruritus
DUPIXENTc
(n=529) n (%)		 1%
PLACEBO
(n=517) n (%)		 <1%
Oral herpes simplex virus infectionf
DUPIXENTc
(n=529) n (%)		 2%
PLACEBO
(n=517) n (%)		 1%
Dry eye
DUPIXENTc
(n=529) n (%)		 <1%
PLACEBO
(n=517) n (%)		 0%
Injection site reaction
DUPIXENT + TCSc
(n=110) n (%)		 10%
PLACEBO + TCS
(n=315) n (%)		 6%
Conjunctivitisd
DUPIXENT + TCSc
(n=110) n (%)		 9%
PLACEBO + TCS
(n=315) n (%)		 5%
Blepharitis
DUPIXENT + TCSc
(n=110) n (%)		 5%
PLACEBO + TCS
(n=315) n (%)		 1%
Oral herpes
DUPIXENT + TCSc
(n=110) n (%)		 3%
PLACEBO + TCS
(n=315) n (%)		 2%
Keratitise
DUPIXENT + TCSc
(n=110) n (%)		 4%
PLACEBO + TCS
(n=315) n (%)		 0%
Eye pruritus
DUPIXENT + TCSc
(n=110) n (%)		 2%
PLACEBO + TCS
(n=315) n (%)		 1%
Oral herpes simplex virus infectionf
DUPIXENT + TCSc
(n=110) n (%)		 1%
PLACEBO + TCS
(n=315) n (%)		 <1%
Dry eye
DUPIXENT + TCSc
(n=110) n (%)		 2%
PLACEBO + TCS
(n=315) n (%)		 <1%

aPooled analysis of Trials 1, 2, and 4 (phase 2 dose-ranging study).

bAnalysis of Trial 3 in which subjects were on background TCS therapy.

cDUPIXENT 600 mg at Week 0, followed by 300 mg every 2 weeks.

dConjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.

eKeratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.

fOther herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex otitis externa, and herpes virus infection, but excludes eczema herpeticum.

  • Most patients experiencing conjunctivitis recovered or were recovering during the treatment period1

Select adverse events in the 52-week trial in adults

  • The rate of serious adverse events with DUPIXENT + TCS was comparable to placebo + TCS (4% vs 5%, respectively)2
  • Keratitis was reported in 4% of the DUPIXENT + TCS group and in 0% of the placebo + TCS group1
  • Conjunctivitis was reported in 16% of the DUPIXENT + TCS group and in 9% of the placebo group + TCS group1
Numerically fewer patients treated with DUPIXENT developed skin infections compared with placebo2
  • 11% vs 18% of adults in Trial 3, respectively
Discontinuation rates in adults due to adverse events with DUPIXENT with or without TCS were comparable to those with placebo1
  • 1.9% of patients treated with DUPIXENT discontinued treatment through Week 16 vs 1.9% of patients treated with placebo through Week 16 (Trials 1, 2, and 4)
  • Similar discontinuation rates occurred at Week 52 in Trial 3 (1.8% with DUPIXENT + TCS vs 7.6% with placebo + TCS)

Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment.1

Avoid use of live vaccines in patients treated with DUPIXENT1

Safety data collected from three phase 3 trials and one dose-ranging trial (Trial 4) (N=2304)1,2

  • 49% had allergic rhinitis
  • 37% had food allergy
  • 27% had allergic conjunctivitis

Safety and efficacy of DUPIXENT have not been established in the treatment of these conditions.1

Important considerations

SAFETY FINDINGS OF DUPIXENT OPEN-LABEL EXTENSION STUDY IN ADULTS FOR UP TO 3 YEARS (TRIAL 9)3

  • Three-year safety datag of DUPIXENT in the open-label study was generally consistent with that of the 52-week controlled trial
  • 3.5% of patients discontinued due to treatment-emergent AEs in the OLE study
    • Study description: This open-label extension study (OLE) of DUPIXENT included adults (n=2677) with moderate-to-severe atopic dermatitis who participated in previous clinical studies or had been screened for a Phase 3 study (Trial 1 or 2), but were not included due to randomization closure. In the OLE study, 2207 patients (82.4%) completed up to Week 52; 1028 (38.4%) up to Week 100; and 347 (13%) up to Week 148. Patients received DUPIXENT 300 mg QW, a different regimen from the FDA-approved 300 mg Q2W dose regimen in adults.

      In DUPIXENT clinical trials, DUPIXENT 300 mg QW did not demonstrate additional treatment benefit over DUPIXENT 300 mg Q2W

    • Limitations of this OLE study included, but were not limited to: no control arm, DUPIXENT-treated patients with serious adverse events or adverse events that led to study drug discontinuation in the parent study were excluded, and just over half of the patients used concomitant TCS/TCIh
gRefers to exposure-adjusted rates of treatment-emergent adverse events and serious adverse events.
hTCI, topical calcineurin inhibitors; TCS, topical corticosteroids.

NO BOXED WARNING1

SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

  • Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT

NOT METABOLIZED THROUGH THE LIVER OR EXCRETED THROUGH THE KIDNEYS1

  • No known drug-to-drug interactions

Please see additional Warnings and Precautions and vaccine information in the Drug Interactions section of the Prescribing Information and Important Safety Information below.

Other attributes1

DUPIXENT IS NOT AN IMMUNOSUPPRESSANT AND AVOIDS BROAD IMMUNOSUPPRESSION

  • It is unknown if DUPIXENT will influence the immune response against helminth infections

NO REQUIREMENT FOR INITIAL LAB TESTING OR ONGOING LAB MONITORING,
according to the Prescribing Information

Dosing and Administration
Thinking about prescribing DUPIXENT? Find the information you need to get started.
Explore ADMINISTRATION Options

References:

  1. DUPIXENT Prescribing Information.
  2. Data on file, Regeneron Pharmaceuticals, Inc.
  3. Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567-577.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indication

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.